VERIGRAFT receives €1.2 million to 3D print arterial grafts

VERIGRAFT, a Swedish biotechnology firm, has been awarded a prestigious Eurostars grant to steer PREPPER (PREcision Printed PERsonalized Tissue Therapies) – a venture growing next-generation 3D printed arterial grafts.

Along with Readily3D SA (Switzerland), RISE (Sweden), and Sahlgrenska College Hospital (Sweden), VERIGRAFT will combine superior 3D printing, solution-blown fiber expertise, and customized tissue engineering. The aim is to create personalized vascular grafts that mimic pure arteries providing superior sturdiness and seamless integration in comparison with present artificial alternate options. The venture has secured €1.2 million in funding and brings collectively internationally acknowledged consultants of their respective fields to drive actual innovation in regenerative drugs.

PREPPER goals to beat the key limitations of present grafts, reminiscent of entry to human-donated materials, poor integration, and excessive failure charges. That is anticipated to pave the way in which for a first-in-human medical trial and future commercialization. The expertise additionally has potential purposes past vascular grafts.

“This Eurostars grant is a serious milestone for VERIGRAFT and regenerative drugs. With PREPPER, we’re accelerating the way forward for customized tissue therapies,” stated Dr. Raimund Strehl, CTO of VERIGRAFT. “The worldwide vascular graft market is projected to exceed $4 billion by 2026, and PREPPER positions Europe on the forefront of 3D bioprinting and regenerative drugs.”

This venture has obtained funding from the Eurostars-3 joint program with co-funding from the European Union’s Horizon Europe analysis and innovation program. Eurostars is a part of the European Partnership on Progressive SMEs.